Division of Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Division of Rheumatology, Department of Pediatrics, Center for Pediatric Clinical Effectiveness, University of Pennsylvania Perelman School of Medicine and Children's Hospital of Philadelphia, Philadelphia, PA, and Division of Immunology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.
Clin Exp Rheumatol. 2022 May;40(5):1045-1051. doi: 10.55563/clinexprheumatol/2xhxrk. Epub 2022 Mar 9.
This study evaluated the clinical features, treatment patterns, and short-term outcomes of children with inflammatory bowel disease (IBD)-associated musculoskeletal manifestations.
This was a retrospective cohort study of children with IBD evaluated for joint complaints in a paediatric rheumatology clinic from 2015 to 2020. The index visit was the date of initial rheumatology evaluation. Clinical features were evaluated using standard descriptive statistics. Differences in outcomes over time were compared using rank-sum tests. Univariate logistic regression was used to test associations between clinical features and persistent arthritis or enthesitis.
Seventy-five patients met inclusion criteria. 61% had active arthritis or enthesitis at initial evaluation, 1/3 of whom were not yet diagnosed with IBD. Of those with known IBD, over half with joint complaints had arthritis or enthesitis. Active joint disease was common even among patients already receiving tumour necrosis factor (TNF) inhibitors or other immunomodulatory medications for IBD and despite inactive gastrointestinal disease. Treatment escalation was often needed to control articular disease, which included changes in immunomodulatory therapy and NSAIDs. Treatment outcomes for arthritis were good and significant improvements in functional mobility were observed (p<0.01), while enthesitis often persisted at follow-up (11/28, 39%). Moreover, a significant proportion of patients with pain at the index visit reported persistent pain at follow-up (29/44, 65%).
This study provides several findings relevant to the multidisciplinary care of children with IBD, including high rates of active arthritis and enthesitis despite ongoing use of immunomodulatory medications for the management of IBD, responses to treatment, and pain management.
本研究评估了炎症性肠病(IBD)相关肌肉骨骼表现患儿的临床特征、治疗模式和短期预后。
这是一项回顾性队列研究,纳入了 2015 年至 2020 年在儿科风湿病诊所因关节问题就诊的 IBD 患儿。索引访视为首次风湿病评估的日期。使用标准描述性统计评估临床特征。使用秩和检验比较随时间变化的结果差异。使用单变量逻辑回归检验临床特征与持续性关节炎或附着点炎之间的关联。
75 例患儿符合纳入标准。61%的患儿在初始评估时存在活动性关节炎或附着点炎,其中 1/3 的患儿尚未诊断为 IBD。在已知患有 IBD 的患儿中,超过一半的关节问题患儿存在关节炎或附着点炎。即使正在接受肿瘤坏死因子(TNF)抑制剂或其他免疫调节剂治疗 IBD 且胃肠道疾病无活动,也常存在活动性关节疾病。为了控制关节疾病,通常需要进行治疗升级,包括改变免疫调节剂治疗和非甾体抗炎药。关节炎的治疗效果良好,观察到功能活动度显著改善(p<0.01),而附着点炎在随访时往往持续存在(11/28,39%)。此外,在索引就诊时报告有疼痛的患儿中,有相当一部分在随访时仍有持续性疼痛(29/44,65%)。
本研究提供了一些与 IBD 患儿多学科管理相关的发现,包括尽管正在使用免疫调节剂治疗 IBD,但仍存在较高的活动性关节炎和附着点炎发生率、治疗反应和疼痛管理。